NCT00725478 (PIR-001/K) is a clinical trial of Piribedil in Parkinson's Disease, sponsored by Desitin Arzneimittel GmbH.

Who is sponsoring NCT00725478?

NCT00725478 is sponsored by Desitin Arzneimittel GmbH.

What drugs are being tested in NCT00725478?

Interventions in NCT00725478: Piribedil.

What condition does NCT00725478 study?

NCT00725478 studies Parkinson's Disease.

Is NCT00725478 still recruiting?

NCT00725478 is currently completed. Last updated 30 March 2010.

Last reviewed 2010-03-30 · How we verify

NCT00725478: PIR-001/K

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.

Completed Last updated 30 March 2010

What this trial tests

trial testing Piribedil in Parkinson's Disease in 250 participants. Completed in 1 June 2008.

Timeline

1 January 2008

Primary endpoint
1 June 2008

1 June 2008

Quick facts

Lead sponsor	Desitin Arzneimittel GmbH
Status	Completed
Study type	OBSERVATIONAL
Enrollment	250
Start date	1 January 2008
Primary completion	1 June 2008
Estimated completion	1 June 2008

Drugs / interventions tested

Piribedil (PIRIBEDIL) — full drug profile →

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

Desitin Arzneimittel GmbH — full company profile →

Who can join

18 and older, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

to monitor use in real practice including adverse events on piribedil
Time frame: 3 months

Sponsor's own description

The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Tolerability and course of the disease or change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists will be documented under routine conditions. Piribedil should be prescribed according to its marketing authorisation by the responsible neurologist.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other Desitin Arzneimittel GmbH trials

Trials by the same sponsor.

NCT07393022 — Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects · Phase 1 · completed
NCT06214130 — Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets · Phase 1 · completed
NCT06211283 — Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects. · Phase 1 · completed
NCT06199791 — Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions · Phase 1 · completed
NCT05236842 — Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00725478 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Desitin Arzneimittel GmbH
Last refreshed: 30 March 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00725478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing